- Home
- PRPO vs HOOK Comparison
PRPO vs HOOK Comparison
Compare PRPO & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- HOOK
- Stock Information
- Founded
- PRPO N/A
- HOOK 2011
- Country
- PRPO United States
- HOOK United States
- Employees
- PRPO N/A
- HOOK N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- HOOK Health Care
- Exchange
- PRPO Nasdaq
- HOOK Nasdaq
- Market Cap
- PRPO 17.1M
- HOOK 15.3M
- IPO Year
- PRPO N/A
- HOOK 2019
- Fundamental
- Price
- PRPO $14.45
- HOOK $1.17
- Analyst Decision
- PRPO
- HOOK Buy
- Analyst Count
- PRPO 0
- HOOK 4
- Target Price
- PRPO N/A
- HOOK $10.67
- AVG Volume (30 Days)
- PRPO 17.7K
- HOOK 57.5K
- Earning Date
- PRPO 08-12-2025
- HOOK 08-07-2025
- Dividend Yield
- PRPO N/A
- HOOK N/A
- EPS Growth
- PRPO N/A
- HOOK N/A
- EPS
- PRPO N/A
- HOOK N/A
- Revenue
- PRPO $20,029,000.00
- HOOK $9,351,000.00
- Revenue This Year
- PRPO N/A
- HOOK N/A
- Revenue Next Year
- PRPO N/A
- HOOK N/A
- P/E Ratio
- PRPO N/A
- HOOK N/A
- Revenue Growth
- PRPO 26.67
- HOOK N/A
- 52 Week Low
- PRPO $3.90
- HOOK $0.72
- 52 Week High
- PRPO $16.89
- HOOK $6.69
- Technical
- Relative Strength Index (RSI)
- PRPO 68.17
- HOOK 35.85
- Support Level
- PRPO $14.25
- HOOK $1.13
- Resistance Level
- PRPO $16.89
- HOOK $1.25
- Average True Range (ATR)
- PRPO 1.08
- HOOK 0.06
- MACD
- PRPO 0.24
- HOOK -0.00
- Stochastic Oscillator
- PRPO 67.57
- HOOK 17.81
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.